Selective estrogen receptor modulators (SERMs) for endometriosis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2014, Pages

  Chen, Ya Li ^a   Zheng, Ai ^b   Wan, Qi ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARZOXIFENE; BAZEDOXIFENE; CENTCHROMAN; DANAZOL; DROLOXIFENE; IDOXIFENE; LASOFOXIFENE; OSPEMIFENE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

ANALGESIA; ARTICLE; CLINICAL OUTCOME; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIOSIS; ENDOMETRIUM CANCER; EVIDENCE BASED MEDICINE; FEMALE FERTILITY; HOT FLUSH; HUMAN; LAPAROSCOPY; META ANALYSIS; OUTCOME ASSESSMENT; PELVIC PAIN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; SYMPTOM; SYSTEMATIC REVIEW; THROMBOSIS; UTERUS BIOPSY; VAGINA BLEEDING;

EID: 85048483676     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011169     Document Type: Article

References (28)

1. Altintas D, Kokcu A, Kandemir B, Tosun M, Cetinkaya MB. Comparison of the effects of raloxifene and anastrozole on experimental endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2010 May;150(1):84-7.
2. Bianconi L, Hummelshoj L,Coccia ME, Vigano P, Vittori G, Veit J, et al. Recognizing endometriosis as a social disease: the European Union-encouraged Italian Senate approach. Fertility and Sterility 2007 Nov;88(5):1285-7.
3. Child TJ, Tan SL. Endometriosis: aetiology, pathogenesis and treatment. Drugs 2001;61:1735-50.
4. Crosignani PG, Olive D, Bergqvist A, Luciano A. Advances in the management of endometriosis: an update for clinicians. Human Reproduction Update 2006;12(2):179-89.
5. D'Hooghe TM, Debrock S. Endometriosis, retrograde menstruation and peritoneal inflammation in women and in baboons. Human Reproduction Update 2002;8(1):84-8.
6. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al.Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. The New England Journal of Medicine 1997;337:1641-7.
7. G.A.J. Dunselman, N. Vermeulen, C. Becker, C. Calhaz-Jorge, T. DHooghe, et al.ESHRE guideline: management of women with endometriosis. Human Reproduction 2014;29(3):400-412.
8. Dutertre M, Smith C. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. The Journal of Pharmacology and Experimental Therapeutics 2000;295(2):431-7.
9. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
10. Eng-Wong J, Zujewski JA. Raloxifene and its role in breast cancer prevention. Expert Review of Anticancer Therapy 2004;4:523-32.
11. Farquhar CM. Clinical evidence. BMJ 2000;320:1449-52.
12. Farquhar C. Endometriosis. BMJ 2007;334:249-53.
13. Francucci CM, Romagni P, Boscaro M. Raloxifene: bone and cardiovascular effects. Journal of Endocrinological Investigation 2005;28(10 Suppl):85-90.
14. Galle PC. Clinical presentation and diagnosis of endometriosis. Obstetrics and Gynecology Clinics of North America 1989;16(1):29-42.
15. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011.Available from www.cochrane-handbook.org.
16. Jones GL, Kennedy SH, Jenkinson C. Health-related quality of life measurement in women with common benign gynecologic conditions: a systematic review. American Journal of Obstetrics and Gynecology 2002;187:501-11.
17. Marques A, Bahamondes L, Aldrighi JM, Petta CA. Quality of life in Brazilian women with endometriosis assessed through a medical outcome questionnaire. The Journal of Reproductive Medicine 2004;49:115-20.
18. Pierzyński P, Swiatecka J, Oczeretko E, Laudański P, Batra S, Laudański T. Effect of short-term, low-dose treatment with tamoxifen in patients with primary dysmenorrhea. Gynecological Endocrinology 2006 Dec;22(12):698-703.
19. Royal College of Obstetricians and Gynaecologists (RCOG). The investigation and management of endometriosis. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG) 2006;24:1-14.
20. Schroder AK, Diedrich K, Ludwig M. Medical management of endometriosis: a systematic review. IDrugs 2004 May;7(5):451-63.
21. Schweppe K-W. Current place of progestins in the treatment of endometriosis-related complaints. Gynecological Endocrinology 2002;15:22-8.
22. Scott JA, da Camara CC, Early JE. Raloxifene: A selective estrogen receptor modulator. American Family Physician 1990;60:1131-9.
23. Silfen SL, Ciaccia AV, Bryant HU. Selective estrogen receptor modulators: tissue selectivity and differential uterine effects. Climacteric 1999;2:268-83.
24. Simsa P, Mihalyi A, Kyama CM, Mwenda JM, Fülöp V, D'Hooghe TM. Selective estrogen-receptor modulators and aromatase inhibitors: promising new medical therapies for endometriosis?. Women's Health 2007;3(5):617-28.
25. Stratton P, Sinaii N, Segars J, Koziol D, Wesley R, Zimmer C, et al.Return of chronic pelvic pain from endometriosis after raloxifene treatment: A randomized controlled trial. Obstetrics and Gynecology 2008 January;111(1):88-96.
26. Thiebaud D, Secrest RJ. Selective estrogen receptor modulators: mechanism of action and clinical experience. Focus on raloxifene. Reproduction, Fertility, and Development 2001;13:331-6.
27. Valle RF, Sciarra JJ. Endometriosis: treatment strategies. Annals of the New York Academy of Sciences 2003;997:229-39.
28. Winkel CA. A cost-effective approach to the management of endometriosis. Current Opinion in Obstetrics and Gynecology 2000;12:317-20.